

## SUPPLEMENTARY FILE

Hepatic cyst infection during use of the somatostatin analogue lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the multicenter, open label, randomized DIPAK-1 study

Drug Safety

Marten A Lantinga<sup>1\*</sup>, MD; Hedwig M.A. D'Agnolo<sup>1\*</sup>, MD; Niek F. Casteleijn<sup>2</sup>, MD; JohanW. de Fijter<sup>3</sup>, MD, PhD; Esther Meijer<sup>2</sup>, MD, PhD; Annemarie.L. Messchendorp<sup>2</sup>, MD; Dorien J.M. Peters<sup>4</sup>, PhD; Mahdi Salih<sup>5</sup>, MD; Edwin M. Spithoven<sup>2</sup>, MD PhD; Darius Soonawala<sup>3</sup>, MD; Folkert W. Visser<sup>2</sup>, MD PhD; Jack F. Wetzels<sup>6</sup>, MD PhD; Bob Zietse<sup>5</sup>, MD PhD; Joost P.H. Drenth<sup>1</sup>, MD, PhD, and Ron T. Gansevoort<sup>2</sup>, MD PhD; on behalf of the DIPAK Consortium

\*both authors contributed equally.

<sup>1</sup> Dept. of Gastroenterology and Hepatology, Radboud University Medical Center Nijmegen, the Netherlands

<sup>2</sup> Dept. of Nephrology, University Medical Center Groningen, the Netherlands

<sup>3</sup> Dept. of Nephrology, Leiden University Medical Center, the Netherlands

<sup>4</sup> Dept. of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands

<sup>5</sup> Dept. of Nephrology, Erasmus Medical Center Rotterdam, the Netherlands

<sup>6</sup> Dept. of Nephrology, Radboud University Medical Center Nijmegen, the Netherlands

**Corresponding author:** Ron T. Gansevoort, MD PhD: [r.t.gansevoort@umcg.nl](mailto:r.t.gansevoort@umcg.nl)

**Content:** Supplement Figure 1 and Legend Supplement Figure 1

**Figure 1.**  $^{18}\text{F}$ -FDG PET/CT results showing signs of hepatic cyst infection in case 1(A) and case 5 (B)

